Muscle Protein Metabolism in Obesity

Regulation of Muscle ATP Synthase Beta Subunit Metabolism in Obesity

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01824173

Enrollment

Registered

2013-04-04

Start date

2012-10-31

Completion date

2020-02-07

Last updated

2020-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

muscle, mitochondria, amino acids, exercise

Brief summary

Obesity is associated with reduced adenosine triphosphate (ATP) turnover in skeletal muscle, a condition that can impair muscle metabolism. The proposed research will discover mechanisms responsible for decreased content in mitochondrial proteins as well as in protein β-F1-ATPase, which is directly responsible for ATP assembly, in the muscle of obese individuals. This research will further examine the effectiveness of interventions, such as increased plasma amino acid availability and exercise, to increase the rate of production of mitochondrial proteins as well as that of β-F1-ATPase in the muscle of obese individuals. The findings will help to develop appropriate interventions to improve muscle ATP turnover and metabolism in obese people.

Interventions

OTHERIncrease in the levels of plasma amino acids

Aminosyn 15%; 160 mg/kg FFM/h for 4 hours

OTHERAerobic exercise

Moderate intensity for 45 minutes

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

1. Body mass index (BMI): lean, 19-26 kg/m2; obese, 30-40 kg/m2 2. Availability of transportation 3. Ability to sign informed consent form

Exclusion criteria

1. Medication or supplements (i.e. amino acids, protein) known to affect protein metabolism 2. Presence of acute illness 3. History of liver disease 4. Uncontrolled metabolic disease 5. ECG documented abnormalities, atrial fibrillation, history of syncope, limiting or unstable angina, or congestive heart failure 6. Chronically elevated blood pressure (systolic, \>140 mmHg; diastolic, \>100 mmHg) 7. Cardiac pacemaker or other medical device implanted in the body 8. Low hemoglobin or hematocrit 9. Current participation in a weight-loss regimen, including extreme dietary practices 10. Smoking 11. Use of anabolic steroids or corticosteroids (within 3 months)

Design outcomes

Primary

Measure	Time frame
Rate of synthesis of muscle proteins (mixed muscle proteins, mitochondrial proteins, β-F1-ATPase)	Measured during a 9-hour infusion study

Secondary

Measure	Time frame
β-F1-ATPase mRNA expression; PGC-1 expression	Measured during a 9-hour infusion study

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 5, 2026